<code id='67E5373979'></code><style id='67E5373979'></style>
      • <acronym id='67E5373979'></acronym>
      <center id='67E5373979'><center id='67E5373979'><tfoot id='67E5373979'></tfoot></center><abbr id='67E5373979'><dir id='67E5373979'><tfoot id='67E5373979'></tfoot><noframes id='67E5373979'>
      • <optgroup id='67E5373979'><strike id='67E5373979'><sup id='67E5373979'></sup></strike><code id='67E5373979'></code></optgroup>
        5. <b id='67E5373979'><label id='67E5373979'><select id='67E5373979'><dt id='67E5373979'><span id='67E5373979'></span></dt></select></label></b><u id='67E5373979'></u>
          <i id='67E5373979'><strike id='67E5373979'><tt id='67E5373979'><pre id='67E5373979'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / focus      
           
     
           
      
          focus 
           
      
           
      
           
       2025-09-29 02:15:01 
   
      
           
      
           
                        
          focus  
          
                                   
                 
                                      author：fashion   
                                        
                                      
                                      Page View：6677
                                  
                                    
          
                                   
          Adobe
          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.
          The deal includes up to another $400 million in payments if certain milestones are met.
          advertisement
          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Leqembi, other new Alzheimer’s drugs require better biomarkers
                                
                            
          Next article：  
                                      
                                          Medicare details structure of new drug price negotiation program
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles